The TFN Complete Guide to Stem Cell Companies Part 4: Share prices below $1
Today's Financial News - Posted November 24, 2008
Baltimore — (TFN): This is a Part 4 of The TFN Complete Guide to Stem Cell Companies.
- Read The TFN Complete Guide to Stem Cell Companies Part 1: Share prices above $50
- Read The TFN Complete Guide to Stem Cell Companies Part 2: Share prices between $10 and $50
- Read The TFN Complete Guide to Stem Cell Companies Part 3: Share prices between $1 and $10
The following prices are as of September 21, 2009.
Stem Cell Stocks Trading Under $1
Angel Biotechnology Holdings Plc (LON:ABH)
Market Cap: $4.48 million
Angel Biotechnology Holdings Plc manufactures and supplies biomaterials for use in clinical trials through all phases of the drug development process and for product launch.
Stock price: $0.31
http://www.angelbio.com
Advanced Cell Technology, Inc. (OTC:ACTC)
Market Cap: $72.49 million
Advanced Cell Technology, Inc. develops and commercializes human embryonic and adult stem cell technology in the field of regenerative medicine.
Stock price: $0.14
http://www.advancedcell.com
Aeolus Pharmaceuticals, Inc. (OTC:AOLS)
Market Cap: $11.24 million
Aeolus Pharmaceuticals, Inc. develops catalytic antioxidant compounds for diseases and disorders of the central nervous system, respiratory system, autoimmune system and oncology. The company’s initial target applications are for the side effects of mustard gas exposure, cancer radiation therapy and amyotrophic lateral sclerosis (ALS).
Stock price: $0.30
http://www.aeoluspharma.com
Aastrom Biosciences, Inc. (NASDAQ:ASTM)
Market Cap: $69.32 million
Aastrom Biosciences, Inc. develops autologous cell products for the repair or regeneration of human tissue.
Stock price: $0.41
http://www.aastrom.com/
BrainStorm Cell Therapeutics Inc. (OTC:BCLI)
Market Cap: $16.74 million
BrainStorm Cell Therapeutics, Inc. develops stem cell technologies as treatments for currently incurable neurodegenerative diseases. The company primarily focuses on developing NTF cells from a patient’s own bone marrow in order to treat Parkinson, ALS, and spinal cord injury.
Stock price: $0.28
http://www.brainstorm-cell.com/
Cell Genesys, Inc. (NASDAQ:CEGE)
Market Cap: $36.18 million
Cell Genesys, Inc. develops and commercializes biological therapies for patients with cancer.
Stock price: $0.33
http://www.cellgenesys.com
Cordlife Ltd. (PINK:CORFF)
Market Cap: $Not Available
CordLife Ltd owns and operates the largest network of private cord blood banks in the Asia Pacific region.
Stock price: $0.39
http://www.cordlife.com/
Forticell Bioscience, Inc. (OTC:FORB)
Market Cap: $801,481.00
Forticell Bioscience, Inc. is a development stage tissue engineering company with capabilities in cell culturing, biology and biomaterials.
Stock price: $0.06
http://www.forticellbioscience.com
PharmaGap Inc. (CVE:GAP)
Market Cap: $24.00 million
PharmaGap Inc. designs and develops therapeutic drugs for the treatment of cancer and other human diseases associated with the human Protein Kinase C enzyme (PKC). PKC is expressed in abnormal levels in many types of cancer and other diseases, such as diabetes.
Stock price: $0.27
http://www.pharmagap.com/
HemaCare Corporation (OTC:HEMA)
Market Cap: $8.03 million
HemaCare Corporation collects, processes and distributes blood products to hospitals and research related organizations. It operates and manages donor centers and mobile donor vehicles to collect transfusable blood products. Additionally, HemaCare provides blood related services, principally therapeutic apheresis procedures, stem cell collection and other blood treatments to patients with a variety of disorders.
Stock price: $0.79
http://www.hemacare.com/
International Stem Cell Corporation (OTC:ISCO)
Market Cap: $41.69 million
International Stem Cell develops therapeutic and research products with the objective of creating an unlimited source of human cells for use in the treatment of several diseases, including diabetes, liver disease and retinal and corneal disease through cell transplant therapy. To assist with this, it has developed pluripotent human stem cells from unfertilized human eggs, and techniques to cause those stem cells to be “differentiated” into the specific cell types required for transplant.
Stock price: $0.87
http://www.internationalstemcell.com/
ThermoGenesis Corp. (NASDAQ:KOOL)
Market Cap: $33.66 million
ThermoGenesis Corp. designs, manufactures and markets automated and semi-automated devices and single-use processing disposables that enable hospitals and blood banks to manufacture a therapeutic dose of stem cells, wound healing proteins or growth factors from a single unit of cord blood or the patient’s own blood in less than one hour.
Stock price: $0.60
http://www.thermogenesis.com/
Lifebank Corp. (CVE:LBK)
Market Cap: $1.77 million
Lifebank Corp. cryopreserves umbilical cord blood stem cells for families.
Stock price: $0.18
http://www.lifebank.com/
Orchestra Therapeutics, Inc. (OTC:OCHT)
Market Cap: $842,214.00
Orchestra Therapeutics, Inc., develops products to treat autoimmune and infectious diseases.
Stock price: $0.08
http://www.orchestratherapeutics.com
Protide Pharmaceuticals, Inc. (OTC:PPMD)
Market Cap: $362,622.00
Protide Pharmaceuticals, Inc. develops and commercializes technologies and processes in clinical cell therapy, transfusion medicine, cell engineering and transplantation.
Stock price: $0.09
http://www.protidepharma.com
RegeneRx Biopharmaceuticals, Inc. (AMEX:RGN)
Market Cap: $38.27 million
RegeneRx Biopharmaceuticals, Inc. develops molecules to promote tissue and organ repair.
Stock price: $0.73
http://www.regenerx.com/
Stem Cell Therapeutics (PINK:SCTPF)
Market Cap: $9.77 million
Stem Cell Therapeutics Corp. develops and commercializes drug-based therapies to treat central nervous system diseases that stimulate a patient’s own resident stem cells.
Stock price: $0.12
http://www.stemcellthera.com/
Vitro Diagnostics, Inc. (OTC:VODG)
Market Cap: $Not Available
Vitro Diagnostics, Inc. develops and commercializes products derived from its human cell line research — predominantly related to diabetes. Vitro has created a patent-pending method to generate adult stem cells from tissues. The Company plans to extend their product line to include stem cell-derived human beta islet cells for use in research and drug discovery.
Stock price: $0.29
http://www.vitrodiag.com/
Read the rest of this TFN Research Report:
- The TFN Complete Guide to Stem Cell Companies Part 1: Share prices above $50
- The TFN Complete Guide to Stem Cell Companies Part 2: Share prices between $10 and $50
- The TFN Complete Guide to Stem Cell Companies Part 3: Share prices between $1 and $10
Next Article: Russian war games: Take advantage of growing hostility
8 Responses to “The TFN Complete Guide to Stem Cell Companies Part 4: Share prices below $1”
Your comments are welcome
Follow TFN via RSS or Twitter |
 |
 |
 |
Advertisement
Latest Headlines
- The Big Picture for Sinobiopharma, Inc. (SNBP)
- Beazer Homes USA, Inc. (BZH) and Hovnanian Enterprises, Inc. (HOV) up despite horrid housing news
- The FDA catalyst: 2010 moves in MannKind (MNKD), Roche Holding (RHHBY), Acorda Therapeutics (ACOR) show it still works!
- Steepest drop since Feb. 2009: Here we go again!
- Is the silver run over? Coeur d’Alene Mines (CDE), Silver Wheaton (SLW), Alto Group (ALTO), Hecla Mining (HL), Endeavour Silver (EXK) close down
January 28th, 2009 at 3:58 am
what about innovation stem cell SCLL pk
January 28th, 2009 at 10:18 am
Hello Mr. Shimoon:
We did not include stocks that were trading for less than 1 cent. Almost any mention can falsely elevate such a tiny company’s shares.
February 4th, 2009 at 11:35 pm
I wish I would have had more knowledge on the subject matter back in Nov or Dec excellent resource!!!
April 16th, 2009 at 1:59 pm
Thanks for the stock information, I will be looking forward to your future emails
Sincerely
Jerry Moeller
May 14th, 2009 at 10:50 pm
I have been following your stock picks but am unable to invest due to sharebuilder does not recconize or allow your picks. Do you have any info on investment site that do allow your picks. I have read up on some that allow otc but not pink sheet etc. Thanks and keep up what you do.
May 18th, 2009 at 4:27 pm
Wow…I’m just beginning to get my tiny feet wet.
I read everything I can online and TFN’s FREE eLetters
has been a great blessing for me as I don’t have
much to play around with so would like to get the
least possible risk shares that I can, while I’m learning.
I started studying the markets just before everything
went for a big dump with the banks and housing.
Probably have learned more in that year or less
than most people in 10 years to a lifetime.
So I thank you again TFN for all the information
you so willingly provide for free.
I hope to purchase some reports later on.
Thank you.
May 19th, 2009 at 10:35 am
Hello Mr. Summerlin:
I’m not sure exactly which companies do allow OTC trades but you could try these guys out…
Charles Schwab and Company:
https://www.schwab.com/public/schwab/home/welcomep.html
1-866-855-9102
E-Trade:
https://us.etrade.com/e/t/home
1-800-387-2331
Euro Pacific Capital:
http://www.europac.net/stocks-buy-foreign.asp
1-800-727-7922
EverTrade Direct Brokerage:
http://www.everbank.com/001Brokerage.aspx
1-888-882-3837
Hope that helps!
Laura
September 11th, 2009 at 8:48 am
i am happy to have found your website, if reference to stem cell stocks, what is holding up research, now that obama is in, you might think that hope would fuel research to begin. gene digiovacchino